REMARKS

In response to the Office Action dated June 23, 2009, Applicants respectfully submit the Remarks, and reconsideration is respectfully requested. Claims 1-14 have been canceled, and claims 15-25 remain in the application.

Amendment to Specification

The fourth paragraph at page 9, lines 13-14 has been amended to define the abbreviations of H.I.V. and C.M.V. as human immunodeficiency virus and cytomegavirus. These abbreviations are well known in the art, and thus one of skill in the art would clearly understand that the abbreviations of H.I.V. and C.M.V. refer to human immunodeficiency virus and cytomegavirus.

No new matter has been added. Hence, Applicants respectfully request consideration and entry of this amendment.

Amendment to Claims 15, 20, 22 and 24

Applicants respectfully submit that claims 15, 20, 22 and 24 have been amended to clearly define the present invention. Applicants respectfully submit that claim 15 has been amended to correct minor grammatical errors and to incorporate the subjected matter recited in claims 16 and 18. Claims 16 and 18 have been cancelled.

Applicants also respectfully submit that claims 20, 22 and 24 have been amended to clarify the claimed subject matter of the present invention. Specifically, claims 20, 22 and 24 have been amended as suggested by the Examiner under Item 5 at page 3 of the Office Action. These claims have been amended to properly recite a Markush group to conform to U.S. practice as suggested by the Examiner. Also,

claim 24 has been amended to replace the abbreviations of H.I.V. and C.M.V. with human immunodeficiency virus and cytomegavirus as suggested by the Examiner to conform to U.S. practice.

Support for these amended claims can be found throughout the specification, particularly in the original claims and in the example. No new matter has been added. Hence, Applicants respectfully request consideration and entry of these claims.

The present invention

Applicants respectfully submit that the present invention is directed to an in vitro serological diagnosis method for detecting the presence of antibodies specific to an infectious microbial agent in a sample to be tested.

The method of the present invention comprises (a) depositing on a solid substrate a first antigen Ag₁ comprising a whole Staphylococcus aureus bacterium which comprises protein A and at least one second antigen Ag₂, wherein said second antigen Ag₂ is an infectious microbial agent; (b) contacting said first antigen Ag₁ and said at least one second antigen Ag₂ with a sample to be tested causing said first antigen Ag₁ and said at least one second Ag₂ to react with a sample to be tested; (c) detecting whether a human immunoglobulin Ac₁ in said human serum reacts with said first antigen Ag₁ by causing the reaction product Ag₁-Ac₁ to react with a detection substance; and (d) providing a controlled sample containing a human serum to be tested for detecting whether said human immunoglobulin react with said first antigen.

The detection substance of the present invention reacts with said human immunoglobulin and not with said first antigen (Ag₁), and the reaction product of

Ag₁-Ac₁ is formed from the reaction of said human immunoglobulin Ac₁ and said first antigen Ag₁;

In addition, the detection substance of the present invention is a secondary detection antibody Ac₂ which is a labeled anti-human immunoglobulin which does not react with protein A and is labeled by fluorescent marking.

Summary of the Office Action

In the Office Action, claims 20, 22 and 24 have been rejected under 35 USC § 112, 2nd paragraph for being indefinite. Claims 15-21 and 24-25 have been rejected under 35 USC § 103 (a) for being unpatentable over Dorval et al. (US Patent No. 5,561,045) in view of Hanke (DE 100 00322A1). In addition, claims 22 and 23 have been rejected under 35 USC § 103 (a) for being unpatentable over Dorval et al. (US Patent No. 5,561,045) and Hanke (DE 100 00322A1) in view of La Scola et al. (Journal of Clinical Microbology, 1996; 34(9): 2270-2274).

Rejection under 35 USC § 112, 2nd paragraph

Claims 20, 22 and 24 have been rejected under 35 USC § 112, 2nd paragraph for being indefinite.

Applicants respectfully submit that claims 20, 22 and 24 have been amended.

Applicants also respectfully submit that claims 20, 22 and 24 have been amended to clarify the claimed subject matter of the present invention. Specifically, claims 20, 22 and 24 have been amended as suggested by the Examiner under Item 5 at page 3 of the Office Action. These claims have been amended to properly recite a Markush group to conform to U.S. practice as suggested by the Examiner. Also, claim 24 has been amended to replace the abbreviations of H.I.V. and C.M.V. with human immunodeficiency virus and cytomegavirus as suggested by the Examiner to

conform to U.S. practice. Support for these amended claims can be found throughout the specification.

No new matter has been added. Hence, Applicants respectfully request consideration and entry of these claims.

First Rejection under 35 USC § 103

Claims 15-21 and 24-25 have been rejected under 35 USC § 103 (a) for being unpatentable over Dorval et al. (US Patent No. 5,561,045) in view of Hanke (DE 100 00322A1). Applicants respectfully traverse.

Applicants respectfully submit that the present invention as recited in the pending claims are neither taught nor suggested by Dorval et al. alone or in combination with Hanke.

Dorval et al.

Applicants respectfully submit that in the Office Action, the Examiner acknowledges that the claimed method of the present invention comprises:

a whole Staphylococcus aureus bacterium immobilized as a so-called first antigen Ag_1 and contacting said first antigen with a sample to be tested, and detecting whether said sample contains a human serum in detecting whether the immobilized reaction product Ag_1 - Ac_1 has reacted with a labeled detection substance (Ac_2), wherein Ac_1 is any human immunoglobulin present in said human serum and wherein said detection substance is a substance reacting with human immunoglobulin and not with said first antigen. (See page 4 of the Office Action.)

Applicants respectfully submit that *Staphylococcus aureus* inherently comprises protein A.

Applicants respectfully submit that Dorval et al. is directed to a method and kit that is different from the claimed invention as recited above and acknowledged by

the Examiner.

Applicants respectfully submit that the Dorval et al. document is directed to a method for simultaneously detecting immunoglobulins including IgG, IgA and/or IgM in a single test assay so that if any of these immunoglobulins have been produced in response to a particular infection agent, such production could be detected which is different from the claimed invention.

In the Office Action, the Examiner alleges that "Dorval et al. teach a solid support with the first antigen containing protein A, a second microbial antigen, the addition of the detection agent which is labeled antihuman immunoglobulin which does not react with protein A. See figures 1A-1F".

Applicants respectfully submit that this allegation is not supported by the Dorval et al. document. Applicants respectfully submit that to the allegation that the "addition of a detection agent which is a labeled antihuman immunoglobulin which does not react with protein A" is erroneous. Applicants respectfully submit that this allegation this is <u>not</u> taught nor suggested by the Dorval et al. document for the reasons presented below.

The Examiner refers to Figures 1A-1F to support the above allegation.

However, support of this allegation <u>cannot</u> be found in the description of Figures 1A-1F, as set forth in columns 10 and 11 of the Doral et al. document.

Applicants respectfully submit that in contradiction to the Examiner's allegation, Figures 1A-1F clearly state that a labeled protein A is used as a detecting substance. Column 11, lines 18-19 of the Dorval et al. document clearly states that "according to the assay, the detection reagent includes protein A (36) coupled to a hydrophobic label, specifically indigo."

Applicants respectfully submit that although protein A is immobilized on a support solid, this immobilized protein A reacts with IgG of all specificities present in the sample (see figure 1B) and the detection substance between immobilized protein A and IgG (see figure 1C) is protein A labeled with indigo (36) to detect the reaction product PA-IgG.

Applicants also respectfully submit that according to the Dorval et al. document, labeled protein A is used in combination with two other detection reagents as shown in Figures 1C, and as recited in column 11, line 21: "the reagent also includes anti-IgA-IgG 38...and anti-IgM-IgG 40...indigo is coupled to each of anti-IgA-IgG 38 and anti-IgM-IgG 40...".

In fact, in the Dorval et al. document, the problem is to detect simultaneously immunoglobulins including IgG, IgA and/or IgM in a single test assay so that if any of these imunoglobulins have been produced in response to a particular infection agent, such production could be detected.

Applicants respectfully submit that according to the Dorval et al. document, a labeled protein A is used to determine the presence of IgG while labeled anti-IgA-IgG or labeled anti-IgM-IgG is used to determine the presence of IgA or, respectively, IgM. However, when such agents are used together, the labeled protein A can bind to the labeled anti-IgA-IgG and anti-IgM-IgG. (See column 5, lines 50-62 of the Dorval et al. document).

Applicants respectfully submit that column 10, lines 24, 25, 26 of the Dorval et al. document clearly recites that "the invention is useful whenever it is desirable to prevent the interaction of two detection reagents with one another". According to Dorval et al., a blocking agent is used to prevent interaction between the two

detection reagents, namely protein A and anti-IgA-IgG or anti-IgM-IgG.

Column 10, lines 2-3 of the Dorval et al. document clearly recites that "preferably, these labeled immunoglobulins are blocked with the label itself and the detection reagent includes labeled protein A, labeled and blocked anti-lgA-lgG and labeled and blocked ani-lgM-lgG. According to the assay of Dorval et al., the detection reagent includes protein A 36 coupled to a hydrophobic label, specifically indigo, which binds to lgG bound to protein A at area 12 of surface 10 and to lgG bound to HIV at area 16 of surface 10. The reagent also includes anti-lgA-lgG 38 which binds to lgA bound to IgV at area 16 of surface 10 and anti-lgM-lgG 40 which binds to lgM bound to HIV at area 16 of surface 100. More specifically, as specified in column 11, lines 24-27, "indigo (the label) is coupled to each of anti-lgA-lgG 38 and anti-lgM-lgG 40, serving both as a label and a blocking agent blocking the biding site of each from interaction with a protein A."

In view of the above, Applicants respectfully submit that the invention of Dorval et al. is different from the claimed invention.

Applicants respectfully submit that the present invention is directed to a detection substance that does not comprise a labeled protein A but an anti human immunoglobulin that does not reacting with protein A as recited in amended claim 15.

Applicants also respectfully submit that there is nothing in the Dorval et al. document that teaches or suggests that the protein A can be used as a control antigen for determining whether or not a negative serum sample is due to the absence of reaction with a serum, let alone a controlled sample to be tested containing a human serum.

In addition, Applicants respectfully submit that in the method of Dorval et al.,

only protein A is used instead of the entire Staphylococcus aureus bacterium as recited in the claims of the present invention.

Hanke

Applicants respectfully submit that Hanke neither teaches nor suggests the claimed invention.

The Hanke document relates to immune-whether-guide-mature. Hanke does not teach or suggest using the entiree Staphylococcus aureus as a control antigen immobilized on a solid support to detect antibodies specific to an infectious microbial agent as claimed in the present invention.

Applicants respectfully submit that the use of the entire Staphylococcus aureus bacteria in the present invention is advantageous because:

- it is a corpuscular antigen control which is easier and reliable to adsorb onto a solid substrate when deposited thereon, and
- the detection by visualisation of a corpuscular control agent is much more reliable and easier to detect than the visualisation of an immunological reaction between an immunoglobulin and a purified protein adsorbed on a solid substrate, especially with a fluorescent marking.

Applicants respectfully submit that in view of the above, there is nothing in the Hanke document that teaches or suggests the claims of the present invention.

Combined teaching of Dorval et al. and Hanke

Again, Applicants respectfully submit that neither the Dorval et al. document nor the Hanke document teaches or suggests the use of the entire Staphylococcus aureus bacterium to detect the presence of antibodies specific to an infectious microbial agent as recited in the claims of the present invention.

In addition, neither the Dorval et al. document or the Hanke document teaches or suggests a method or kit for detecting whether the tested sample contains a human serum by detecting whether said detection substance consisting in an anti human immunoglobulin react or not with a human immunoglobulin-first antigen reaction product as reacted with the said detection substance as claimed in the present invention.

In view of all the differences and advantages of the claimed present invention discussed above, Applicants respectfully submit that one of ordinary skill in the art would be motivated to utilize the teaching of Dorval et al. either alone or in combination with Hanke at the time of the invention was invented to modify the method taught by Dorval et al. to arrive at the claimed invention in order to provide an easy control test of the presence of a human serum in the sample tested in the serological diagnosis method.

Hence, Applicants respectfully request reconsideration and withdrawal of this rejection.

Second Rejection under 35 USC § 103

In addition, claims 22 and 23 have been rejected under 35 USC § 103 (a) for being unpatentable over Dorval et al. (US Patent No. 5,561,045) and Hanke (DE 100 00322A1) in view of La Scola et al. (Journal of Clinical Microbology, 1996; 34(9): 2270-2274). Applicants respectfully traverse.

Dorval et al. and Hanke

As discussed above, Applicants respectfully submit that neither the Dorval et al. document nor the Hanke document teaches or suggests the use of the entire Staphylococcus aureus bacterium to detect the presence of antibodies specific to an

infectious microbial agent as recited in the claims of the present invention.

In addition, neither the Dorval et al. document or the Hanke document teaches or suggests a method or kit for detecting whether the tested sample contains a human serum by detecting whether said detection substance consisting in an anti human immunoglobulin react or not with a human immunoglobulin-first antigen reaction product as reacted with the said detection substance as claimed in the present invention.

<u>La Scola et al.</u>

As for the La Scola et al. document, this document cannot be used to cure the deficiencies of the Dorval et al. document.

Applicants respectfully submit that La Scola et al. disclose serological crossreactions between *Bartonella quintana*, *Bartonella henselae*, and *Coxiella burnetti*.

Applicants respectfully submit that La Scola et al. neither teach nor suggest a method or kit for detecting the presence of antibodies specific to an infectious microbial agent in a sample to be tested using a whole *Staphylococcus aureus* as recited in the claims of the present invention. Further, the La Scola et al. document neither teaches nor suggests a method comprising (a) depositing on a solid substrate a first antigen Ag₁ comprising a whole Staphylococcus aureus bacterium and at least one second antigen Ag₂; (b) contacting said first antigen Ag₁ and said at least one second antigen Ag₂ with a sample to be tested causing said first antigen Ag₁ and said at least one second Ag₂ to react with a sample to be tested; (c) detecting whether a human immunoglobulin Ac₁ in said human serum reacts with said first antigen Ag₁ by causing the reaction product Ag₁-Ac₁ to react with a detection substance; and (d) providing a controlled sample containing a human

serum to be tested for detecting whether said human immunoglobulin react with said detection substance has reacted with the reaction product as recited in the claims of the present invention.

Combined teaching of Dorval et al., Hanke, and La Scola et al.

Therefore, one of ordinary skill in the art would not be motivated to combine the teaching of Dorval et al. with the teaching of Hanke and La Scola et al. to make the present invention.

In view of the above, Applicants respectfully request reconsideration and withdrawal of this rejection.

CONCLUSION

In light of the foregoing Remarks, Applicants respectfully submit that the application is now in condition for examination.

Should any minor matter remain, or should the Examiner feel that an interview would expedite the prosecution of this application, the Examiner is invited to call the undersigned to arrange such.

To the extent necessary, Applicant petitions for an extension of time under 37 CFR 1.136. Please charge any shortage in the fees due in connection with the filing of this paper, including extension of time fees, to the deposit account of Antonelli, Terry, Stout & Kraus, LLP, Deposit Account No. 01-2135 (Case: 935.44544X00), and please credit any excess fees to such deposit account.

Respectfully submitted,

ANTONELLI, TERRY, STOUT & KRAUS, LLP

/Jessica H. Bui/ Jessica H. Bui Registration No. 40,846

JHB/kmh (703) 312-6600